Pelubiprofen was also non-inferior to celecoxib in terms of the secondary end points , such as , decrease in KHAQ score ( 0.0 0.5 , 97.5 % CI -0.2 to ) , decrease in duration of morning stiffness ( median 0.0 minute in both groups ) , and decrease in the frequency ( 0.7 3.5 , 97.5 % CI -0.6 to ) and total amount ( 0.7 3.6 , 97.5 % CI -0.6 to ) of rescue medication uses during the 6 week study period .